SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

BriaCell Therapeutics Corp. BCTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

BriaCell Therapeutics Corp. (BCTX) is a Biotechnology company in the Healthcare sector, currently trading at $4.54. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: BCTX trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25).

Net income is $36M (loss), growing at -224.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $25M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.01 (strong liquidity). Debt-to-assets is 0%. Total assets: $30M.

Analyst outlook: 1 / 1 analysts rate BCTX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

BCTX SharesGrow Score Overview

62/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BCTX

BCTX trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25). Trailing PEG 0.11. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

BCTX: +0%/yr revenue is, -224.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet BCTX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 5.01 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BCTX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate BCTX as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range3.6-98.2

Volume140.96K

Avg Volume (30D)296.22K

Market Cap$8.55M

Beta (1Y)1.63

Share Statistics

EPS (TTM)-86.25

Shares Outstanding$1.88M

IPO Date2012-03-14

Employees16

CEOWilliam V. Williams

Financial Highlights & Ratios

Gross Profit$-147.89K

EBITDA$-36.63M

Net Income$-36.5M

Operating Income$-37.73M

Total Cash$24.56M

Net Debt$-14.43M

Total Assets$29.77M

Price / Earnings (P/E)-0.1

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryCA

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINCA1079303071

Price Chart

BCTX

BriaCell Therapeutics Corp. ↗ · NASDAQ Capital Marke

Healthcare • Biotechnology

3.60 52WK RANGE 98.20

People Also View

Terns Pharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

Inozyme Pharma, Inc.

PDS Biotechnology Corporation

Mereo BioPharma Group plc

X4 Pharmaceuticals, Inc.

Elevation Oncology, Inc.

HOOKIPA Pharma Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message